H.R. 10571 · 119th Congress · Health
Surge to Save Newborns Act
- IntroducedSep 24, 2026 Done
- CommitteeReferred to Energy and Commerce Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 306 wordsH.R. 10571 · Introduced in House · Sep 24, 2026
This Act may be cited as the Surge to Save Newborns Act .
The Public Health Service Act is amended by inserting after section 330C ( 42 U.S.C. 254c–3 ) the following:
(a) Establishment. The Secretary shall establish a program to provide grants to States for timely implementation of newborn screening for conditions on the recommended uniform screening panel maintained by the Secretary (or any successor panel).
(b) Eligibility. To be eligible to receive a grant under this section, an entity shall— (1) be— (A) a chief executive officer for health of a State, or the designee of such officer; or (B) a State governmental agency; and (2) shall submit to the Secretary an application— (A) at such time and in such manner as the Secretary may require; and (B) containing a description of how the entity proposes to use grant funds for implementation of newborn screening for conditions on the recommended uniform screening panel referred to in subsection (a).
(c) Annual reports. Not later than the end of fiscal year 2027, and each fiscal year thereafter through the end of fiscal year 2031, the Secretary shall submit to Congress a report that includes— (1) a State-by-State identification of newborn screening implementation for conditions on the recommend uniform screening panel referred to in subsection (a), including— (A) associated conditions; and (B) for each State, the specific conditions for which screening has not been implemented; (2) an evaluation of the effectiveness of grants under this section; and (3) any recommendations of the Secretary for legislative or administrative action.
(d) Funding. Out of any money in the Treasury not otherwise appropriated, there is appropriated $35,000,000 for each of fiscal years 2027 through 2031, to remain available until expended, for grants under this section.
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
2 organizations, more than 77% of House bills · 2 filings · Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Biomarin Pharmaceutical Inc.
1 of 1 quarter
“H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING”
$1.1M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Orchard Therapeutics North America
1 of 1 quarter
“FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act”
$900K lobbying spend in 2026 to date, all issuesQ3 2026 filing
Organizations that named H.R. 10571 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Sep 24, 2026Referred to the House Committee on Energy and Commerce.
- Sep 24, 2026Introduced in House